We ended the quarter with cash and investments of $7.7 billion, compared with $7.2 billion last quarter. your options for e-mail notification, please enter your e-mail address below and click On a constant currency basis, fourth quarter 2022 revenue increased 10% compared to the fourth quarter of 2021. You may automatically receive Intuitive Surgical financial information by e-mail. I don't know how much of an update you can give us, but just something on what's happening at that level in terms of software tools and services? Later we will have a question-and-answer session. In Q2, U.S. procedures grew 77% year over year, which equates to 16% on a two-year compound annual growth rate basis. The call will be webcast by Nasdaq OMX and can be accessed on Intuitives website at www.intuitive.com or by dialing (877) 692-8955 using the access code 5830756. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release. Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. A reconciliation between our pro forma and GAAP results is posted on our website. So when we talk about My Intuitive, that really is putting the power of interaction and data at the surgeon level in their hands or at the robotics coordinator level in their hands. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to, the following: the risk that the COVID-19 pandemic could lead to further material delays and cancellations of, or reduced demand for, procedures; curtailed or delayed capital spending by hospitals; disruption to our supply chain, including increased difficulties in obtaining a sufficient amount of materials in the semiconductor and other markets; closures of our facilities; delays in surgeon training; delays in gathering clinical evidence; delays in obtaining new product approvals or clearances from the U.S. Food and Drug Administration (FDA) due to the effects of the COVID-19 pandemic; the evaluation of the risks of robotic-assisted surgery in the presence of infectious diseases; diversion of management and other resources to respond to the COVID-19 outbreaks; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 pandemic continues to disrupt local economies and causes economies in our key markets to enter prolonged recessions; the risk of our inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and market acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including our joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; our completion of and ability to successfully integrate acquisitions, including Orpheus Medical; procedures counts; regulatory approvals, clearances, and restrictions or any dispute that may occur with any regulatory body; guidelines and recommendations in the healthcare and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets in which we operate; risks associated with our operations outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; our reliance on sole and single source suppliers; the results of legal proceedings to which we are or may become a party; product liability and other litigation claims; adverse publicity regarding us and the safety of our products and adequacy of training; our ability to expand into foreign markets; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements; and other risk factors. We also -- the business came back faster than we had anticipated. These system-controlled staplers, vessel sealers, and energy instruments support a range of procedures from bariatrics to colorectal procedures, to thoracic and gynecologic applications. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. How close we are to maybe seeing something that you can monetize? *Stock Advisor returns as of June 7, 2021. Are we starting to see leverage potentially that could enable a little bit better margins as we think about next year, year after? Both gynecology and urology procedure annualized growth strengthened in the quarter, as pandemic pressures eased in the U.S. An accomplished communicator seeking opportunities in Ottawa, with a proven ability to multitask under high-pressure situations to meet deadlines. Non-GAAP net income attributable to Intuitive Surgical, Inc. and EPS. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS and evaluating non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS together with net income attributable to Intuitive Surgical, Inc. and net income per share attributable to Intuitive Surgical, Inc. calculated in accordance with GAAP. Long-term incentive plan expense relates to phantom share awards granted in China by the Companys joint venture, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., to its employees that vest over four years and can remain outstanding for seven to ten years. SBC expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Companys business. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding items such as amortization of intangible assets, share-based compensation (SBC) and long-term incentive plan expenses, and other special items. However, that charge generated -- that change generated a long-term benefit of $66 million that is recognized currently in GAAP income and will be recognized ratably over approximately 10 years in pro forma income. Intangible asset charges consist of non-cash charges, such as the amortization of intangible assets as well as in-process R&D charges. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints. Fourth quarter 2021 revenue was$1.55 billion, an increase of 17%compared with$1.33 billion in thefourth quarter of 2020. All of that, to me, indicates that the business feels in balance. It last split in October of 2017. Non-GAAP gross profit. Bringing it all together. The increase in cash in the second quarter primarily reflected cash from operations and stock exercises. ISRG stock has split before. Contact Information. You're developing, trying to increase efficiency, decrease costs, that kind of thing. Sure. Just a couple of comments. I will now turn to our financial outlook for 2021. Data Provided by Refinitiv. The rise in earnings was driven by higher . System placements came in above plan, and system ASP and I&A revenue per procedure tracked slightly above our expectations, together driving revenue of $1.46 billion in Q2. Thanks. The Company ended the fourth quarter of 2022 with $6.74 billion in cash, cash equivalents, and investments, a decrease of $651 million during the quarter, primarily driven by share repurchases of $1 billion and capital expenditures, partially offset by cash generated from operations. Go ahead, Mr. Hopkins. We know that new system placements are closely tied to anticipated procedure volumes and system utilization in mature markets. Procedure growth in the U.S. was led by bariatric cholecystectomy and hernia procedures. Trade-in activity can fluctuate and be difficult to predict. Fourth quarter 2022 constant currency revenue increased 10% compared to the fourth quarter of 2021. I just wondered, are you suggesting or should we be thinking that we could be in the front of a new wave of capital acquisition, with again, capital released because of the need to add additional systems to accommodate the expanding number of procedures? And we're building into the broader digital ecosystem for SP. The compound annual growth rate between the fourth quarter of 2019 and the fourth quarter of 2021 was 12%. For more information, please visit the Companys website at www.intuitive.com. Additionally, constant currency revenue growth is reported on a non-GAAP* basis. The Company believes these non-GAAP financial measures are useful to investors, because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Companys business. It's physically demanding. And our posture to that has been -- it may delay some sales as we may have some competitive conversations and tenders, and we'll lose some. Can you talk about kind of next steps to the program here, particular geographies you're targeting? These non-GAAP financial measures also facilitate managements internal comparisons to its historical performance. And at this time, I would like to turn the conference over to our host, senior director of finance, investor relations for Intuitive, Mr. Calvin Darling. Accordingly, they are subject to significant volatility based on the performance of these metrics and are not tied to performance of the Companys business within the period. Total second-quarter revenue was $1.464 billion, representing a 72% increase from last year and a 13% increase from last quarter. The Company defines non-GAAP net income as net income attributable to Intuitive Surgical, Inc., excluding intangible asset charges, non-cash impairment charges and recoveries, certain acquisition-related items for the re-measurement of contingent consideration, SBC and long-term incentive plan expenses, litigation charges and recoveries, gains (losses) on strategic investments, adjustments attributable to noncontrolling interest in joint venture, net of the related tax effects, and tax adjustments, including the excess tax benefits or deficiencies associated with SBC arrangements, a one-time tax benefit from re-measurement of certain deferred tax assets, and the net tax effects related to intra-entity transfers of non-inventory assets. Our total Ion clinical experience is approximately 4,000 cases to date. Da Vinci systems offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. So several of those things are in the markets, the very first kind of Gen 1, some of them are on Gen 2. Marshall will take you through our financial picture later in the call. We think there's an opportunity to look at correlations between surgeon performance and outcomes. Lease buyout revenue has varied significantly quarter to quarter and will likely continue to do so. Our technologies include the da Vinci surgical system and the Ion endoluminal system. Follow Allison Gatlin on Twitter at @IBD_AGatlin . For full-year 2021, Intuitive Surgical revenues are estimated to be north of $5.7 billion, reflecting a 30% y-o-y growth, while the growth rate is expected to slow to low teens next year . Those things are ongoing now. I think our customers will take their time to evaluate new things as they go. And so we'll spend there. The Company placed 369 da Vinci Surgical Systems, a decrease of 4% compared with 385 in the fourth quarter of 2021. PROCEPT BioRobotics is a surgical robotics company enabling better patient care by developing transformative solutions in urology. Lockdowns decrease patient mobility and willingness to go get their tests and then hospitalization diminishes ICU capacity. Our pro forma spending grew over 24% from a year ago, representing increased investment in our business. So we're making those investments to move that forward. That will play out over the next several quarters as we accrue patients. Yes. We believe value creation in surgery and acute care is foundationally human. Thoracic Surgery Market was valued at USD 3.1 Billion in 2021, and it is expected to reach a CAGR of 7.18 % . Copyright 2023 Intuitive Surgical. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. In other words, happy, very satisfied customers. The pandemic is not behind us, and additional infection growth may again strain hospital resources and impact our results in the future. The Company excludes a one-time tax benefit from re-measurement of certain deferred tax assets, because it is discrete in nature, and excludes the excess tax benefits or deficiencies associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the on-going results of its core operations.